eXoZymes (EXOZ)

Executive Summary

eXoZymes (EXOZ) is a public biotech company pioneering a novel approach to small molecule synthesis by using optimized enzymes. Unlike traditional petrochemical or nature-isolated methods, eXoZymes designs and evolves enzymes to build complex molecules with high precision, mimicking accelerated evolution. Founded in 2019 and headquartered in the US, the company aims to disrupt the pharmaceutical and chemical industries by offering a sustainable, scalable, and cost-effective alternative for manufacturing active pharmaceutical ingredients (APIs) and other high-value compounds. The platform combines computational design with directed evolution, enabling rapid iteration and production of molecules that are difficult or impossible to make via conventional chemistry. Despite being early-stage with no disclosed pipeline, eXoZymes has attracted attention for its innovative platform technology. With a current valuation of approximately $84.5 million and a public listing, the company is positioned to capitalize on growing demand for green chemistry solutions. Key upcoming catalysts include potential partnerships with pharmaceutical companies seeking alternative manufacturing routes, proof-of-concept data from internal development programs, and progress in scaling its enzyme production. The company's conviction score of 65 reflects its promising technology but limited near-term de-risking events.

Upcoming Catalysts (preview)

• Q4 2026Announcement of strategic partnership with major pharma for enzyme design services40% success
• Q2 2026Release of proof-of-concept data for lead program targeting high-value API50% success
• Q3 2026Grant of key patent covering core enzyme engineering technology70% success